Assistant Professor Jesus Rodriguez Manzano, Co-Founder and CSO at ProtonDx, and Deputy Director of the Centre for Antimicrobial Optimisation (CAMO) at Imperial College, shares his views on the current threat of a ‘tripledemic’ that looms over the Northern hemisphere, including many parts of Europe.

Dr Jesus Rodriguez-Manzano, Co-Founder and Chief Scientific Officer (CSO) at ProtonDx, shares his thoughts on antimicrobial resistance (AMR). He discusses what we can learn from the recent COVID-19 pandemic, including the important role that point-of-need diagnostics can play.

People infected by Covid-19 and influenza face four times the risk of requiring a ventilator and twice the risk of death. Diagnosis of which respiratory viruses are infecting the patient is crucial especially as there is no increased risk of severe illness for those with both Covid-19 and RSV or other respiratory viruses.

Research by Imperial College London suggests that lateral flow tests miss a substantial number of COVID-19 infections, particularly for people without symptoms, emphasising the need for rapid, sensitive, accurate and portable tests.

“Better, faster diagnostics will be central to tackling antimicrobial resistance in the future,” said ProtonDx Founder and Director, Asst Professor Jesus Rodriguez-Manzano, at a recent FORUM event organised by the Academy of Medical Sciences.